Novo Nordisk, under new CEO Doustdar, freezes hiring in non-critical business areas

Novo Nordisk is undergoing a leadership transition to new CEO Maziar Mike Doustdar, effective August 7, amidst significant financial headwinds. The company reported a 'sharp slowdown' in half-year revenue growth to 16% (154.9 billion DKK), tempered its 2025 sales forecast for key semaglutide products, and has seen its share price plummet over 59% in the past year. In response, Novo Nordisk has implemented a hiring freeze, with both former and new leadership signaling potential layoffs and a broader re-evaluation of the cost base, as Doustdar aims to reallocate resources and refocus on core diabetes and obesity segments.

Analysis

Novo Nordisk is navigating a period of significant distress, marked by a leadership change, decelerating growth, and substantial stock price erosion. The appointment of new CEO Maziar Mike Doustdar coincides with the company's half-year revenue growth of 16% being characterized by analysts as a "sharp slowdown." This underperformance is underscored by a more than 59% collapse in its share price over the past year and a downward revision of the 2025 sales growth forecast, attributed to weaker-than-expected performance from key semaglutide products, Ozempic and Wegovy. In response to these "recent market challenges," management is taking immediate corrective action. The company has instituted a hiring freeze in non-critical areas, and both the outgoing and incoming CEOs have explicitly signaled potential layoffs and a comprehensive review of the cost base. Doustdar's stated strategy is to refocus on the core diabetes and obesity segments while reallocating capital to areas with higher growth potential, signaling a significant strategic pivot aimed at stabilization and recovery.

Key Decisions for Investors

• Given the 59% share price decline and slowing growth, investors should exercise caution, as the announced cost-cutting measures and leadership transition introduce significant execution risk.
• Closely monitor upcoming earnings for the performance of semaglutide products Ozempic and Wegovy, as their growth trajectory is critical to reversing the negative outlook that prompted the tempered 2025 forecast.
• Evaluate the new CEO's initial strategic actions, particularly regarding the reallocation of capital and the extent of the cost-base restructuring, as these will be key indicators of a potential turnaround.